A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 200
- Registration Number
- NCT06741397
- Locations
- π΅π·
GSK Investigational Site, San Juan, Puerto Rico
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 168
- Registration Number
- NCT06724640
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 324
- Registration Number
- NCT06694805
- Locations
- π΅π·
GSK Investigational Site, San Juan, Puerto Rico
A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 86
- Registration Number
- NCT06652958
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)
Phase 1
Not yet recruiting
- Conditions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 91
- Registration Number
- NCT06533280
- Locations
- πΊπΈ
GSK Investigational Site, Baltimore, Maryland, United States
A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 36
- Registration Number
- NCT06368986
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
First Time in Human Study of Long Acting VH4524184 Formulations
Phase 1
Recruiting
- Conditions
- Interventions
- Drug: Oral VH4524184Drug: VH4524184 Formulation A SCDrug: VH4524184 Formulation A IMDrug: VH4524184 Formulation B IMDrug: Placebo Formulation B IMDrug: Placebo Formulation A SCDrug: VH4524184 Formulation B SCDrug: VH4524184 Formulation C SCDrug: Placebo Formulation A IMDrug: rHuPH20Drug: Placebo Formulation B SCDrug: Placebo Formulation C SC
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 72
- Registration Number
- NCT06310551
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 26
- Registration Number
- NCT06310616
- Locations
- πΊπΈ
GSK Investigational Site, San Antonio, Texas, United States
VH4524184 Proof-of-Concept in Treatment-NaΓ―ve Adults Living With HIV-1
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 28
- Registration Number
- NCT06214052
- Locations
- πͺπΈ
GSK Investigational Site, Valencia, Spain
A Study to Investigate the Relative Bioavailability and Food Effect of an Oral Capsid Inhibitor Tablet Formulation Compared With Other Oral Tablet Formulations in Male and Female Healthy Participants
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 46
- Registration Number
- NCT06168318
- Locations
- π¬π§
GSK Investigational Site, Nottingham, United Kingdom
Β© Copyright 2024. All Rights Reserved by MedPath